This paper delves into the intricate landscape of global pharmaceutical pricing, examining the diverse factors contributing to price differences across regions, with a specific focus on the United States. Through an exploration of regulatory frameworks, market dynamics, healthcare system structures, and pricing strategies, the study elucidates the complexities shaping drug pricing differentials. By analyzing examples of various drug types such as biologics, cancer drugs, generic drugs, and orphan drugs, the paper underscores the significance of understanding how these factors interact to influence pricing strategies. Furthermore, the research delves into the rationale behind high drug prices in the U.S., emphasizing the impact of research and development costs, market exclusivity, and specialty medication development. Proposing measures to enhance price transparency, including mandating price reporting, establishing price databases, standardizing pricing information, and requiring price justifications, the paper advocates for collaborative efforts, stakeholder engagement, regulatory oversight, and technological advancements to foster a more equitable and competitive pharmaceutical market globally.